title: Treatment results and prognostic factors in locally advanced hypopharyngeal cancer.
abstract: CONCLUSIONS
  We suggest that concurrent chemoradiation (CCRT) is an effective definitive treatment for patients with advanced hypopharyngeal carcinoma who are unfit for or refuse surgery. A high dose of radiation (> 70 Gy) should be given to achieve acceptable local control rates and survival.
  
  
  OBJECTIVE
  The purpose of this retrospective study was to compare the treatment results of locally advanced hypopharyngeal carcinoma with two different protocols.
  
  
  METHODS
  From December 1995 to December 2004, 74 patients with locally advanced hypopharyngeal cancer were treated with CCRT or surgery plus postoperative radiotherapy (SRT). Their treatment results were reviewed by retrospective analysis. The study points included outcome, toxicity, and prognostic factors.
  
  
  RESULTS
  There was no significant difference in T and N status between the two treatment groups, nor were there significant differences in overall or disease-free survival or the incidence of distant metastasis (p >0.05). In the CCRT group and SRT group, the estimated 3-year overall survival was 39% and 44%, respectively. The SRT group had better local control than the CCRT group (p <0.05). Relatively, 27% patients retained their larynx function for more than 2 years in the CCRT group. Radiation doses >70 Gy yielded significantly better survival and local control than doses <70 Gy (p <0.05).
authors.affiliation: Department of Radiation Oncology, Buddhist Dalin Tzu Chi General Hospital, Dalin, Chiayi, Taiwan.
authors.forename: Moon-Sing
authors.initials: MS
authors.lastname: Lee
authors.forename: Hsu-Chueh
authors.initials: HC
authors.lastname: Ho
authors.forename: Shih-Hsuan
authors.initials: SH
authors.lastname: Hsiao
authors.forename: Juen-Haur
authors.initials: JH
authors.lastname: Hwang
authors.forename: Ching-Chih
authors.initials: CC
authors.lastname: Lee
authors.forename: Shih-Kai
authors.initials: SK
authors.lastname: Hung
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D016629:Esophagectomy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D007013:Hypopharynx / Q000473:pathology / Q000601:surgery; D053208:Kaplan-Meier Estimate; D007825:Laryngectomy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010611:Pharyngectomy; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies
chemical_list: D002945:Cisplatin; D005472:Fluorouracil